AHL
KYMR icon

Abel Hall LLC’s Kymera Therapeutics KYMR Stock Holding History

Abel Hall LLC’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$537K Sell
4,681
-152
-3% -$13.1K 0.09% 218
2026
Q1 		$403K Sell
4,833
-1,003
-17% -$79.4K 0.09% 274
2025
Q4 		$454K Buy
+5,836
New +$394K 0.11% 197

Other funds holding KYMR

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LA
LBP AM Paris, France $10B AUM 43.88% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM

Abel Hall LLC's KYMR Position: Q2 2026 in Review

Abel Hall LLC reduced its Kymera Therapeutics (KYMR) stake by 3.1% in Q2 2026, selling an estimated $13.1K and leaving 4,681 shares worth $537K. The position accounts for 0.09% of the portfolio, ranked #218.

Abel Hall LLC first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 41 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Abel Hall LLC held 4,681 shares of Kymera Therapeutics worth $537K as of Q2 2026.
  • Abel Hall LLC sold 152 Kymera Therapeutics shares in Q2 2026, an estimated $13.1K.
  • Kymera Therapeutics made up 0.09% of Abel Hall LLC's portfolio in Q2 2026, its #218 holding.
  • Abel Hall LLC first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 41 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.